EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
- Conditions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 551
- Registration Number
- NCT00562588
- Locations
- π©πͺ
9.182.1 Boehringer Ingelheim Investigational Site, Bad Homburg, Germany
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1068
- Registration Number
- NCT00561925
- Locations
- πΊπΈ
1100.1486.0025 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
πΊπΈ1100.1486.0041 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
πΊπΈ1100.1486.0031 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
- Conditions
- Interventions
- First Posted Date
- 2007-11-19
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 112
- Registration Number
- NCT00560508
- Locations
- π―π΅
248.610.020 Boehringer Ingelheim Investigational Site, Akita, Akita, Japan
π―π΅248.610.019 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
π―π΅248.610.014 Boehringer Ingelheim Investigational Site, Fuchu, Tokyo, Japan
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT00558571
- Locations
- π©πͺ
1245.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
π©πͺ1245.4.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany
π©πͺ1245.4.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
- Conditions
- Interventions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT00558467
- Locations
- πΊπΈ
248.644.0012 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
πΊπΈ248.644.0026 Boehringer Ingelheim Investigational Site, Bradenton, Florida, United States
πΊπΈ248.644.0005 Boehringer Ingelheim Investigational Site, Cambridge, Massachusetts, United States
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
- Conditions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1098
- Registration Number
- NCT00558428
- Locations
- π³π±
1235.5.31004 Boehringer Ingelheim Investigational Site, Hoogwoud, Netherlands
π³π±1235.5.31003 Boehringer Ingelheim Investigational Site, Musselkanaal, Netherlands
π³π±1235.5.31005 Boehringer Ingelheim Investigational Site, Roelofarendsveen, Netherlands
4 Weeks Treatment of Type II Diabetic Patients With BI 44847
- Conditions
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT00558909
- Locations
- π©πͺ
1224.4.49003 Boehringer Ingelheim Investigational Site, Mainz, Germany
π©πͺ1224.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
π©πͺ1224.4.49002 Boehringer Ingelheim Investigational Site, Berlin, Germany
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1353
- Registration Number
- NCT00558259
- Locations
- πΊπΈ
1160.63.01002 Boehringer Ingelheim Investigational Site, Laguna Hills, California, United States
πΊπΈ1160.63.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
πΊπΈ1160.63.01032 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 156
- Registration Number
- NCT00558025
- Locations
- π«π·
248.636.3307C Boehringer Ingelheim Investigational Site, Bron cedex, France
π³π±248.636.31005 Boehringer Ingelheim Investigational Site, 's-hertogenbosch, Netherlands
π«π·248.636.3303B Boehringer Ingelheim Investigational Site, Aix en Provence, France
Filtered Trial for Amlodipine Non-responder
- Conditions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 531
- Registration Number
- NCT00558064
- Locations
- π―π΅
1235.13.009 Boehringer Ingelheim Investigational Site, Kiyose, Tokyo, Japan
π―π΅1235.13.002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi, Japan
π―π΅1235.13.038 Boehringer Ingelheim Investigational Site, Kitaazumi-gun, Nagano, Japan